Shift Bioscience, a Cambridge biotech using an AI powered virtual cell to fight age-related diseases, has made two shrewd hires as it advances its technology. The company has appointed Jill Reckless ...

The global regenerative dentistry market is set for substantial expansion, driven by advancements in cell and molecular ...

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

The Max Planck Institute for Medical Research in Heidelberg will open two new departments in Heilbronn. • Prospects for talented graduates: The funding enables the further development of the Max ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...